Truffle Capital

About Truffle Capital

Truffle Capital is an independent European venture capital firm with €1.2 billion of assets under management as of December 2024, founded in 2001 and headquartered in Paris. The firm focuses on building and financing innovative companies in Life Sciences (MedTech and Biotech) and IT sectors (FinTech and InsurTech), with the platform supporting European early-stage and growth-stage innovation across two core verticals over a multi-decade track record.

Investment thesis

Truffle deploys venture capital across two complementary verticals: Life Sciences (MedTech medical devices, Biotech drug development) and IT (FinTech, InsurTech, enterprise software). Investment stages span early-stage seed and Series A through growth equity commitments, with equity tickets typically ranging from €2 million to €30 million per transaction depending on stage and sub-vertical. The dual vertical focus enables deep scientific and technology expertise across both healthcare innovation and digital finance innovation.

Recent activity

Recent realised exits include RETENCY (software, 2024) and PHARNEXT (software, 2022), reflecting selective distribution activity across the technology portfolio. The platform tracks 3 funds, 8 active portfolio companies and 7 realised exits across the dual Life Sciences and IT venture programme. Detailed buyer names and multiple data available on Pro at €29/month.